The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men

[1]  C. Block,et al.  Mechanisms linking obesity with cardiovascular disease , 2006, Nature.

[2]  D. Cota,et al.  The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.

[3]  M. Gonthier,et al.  Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes , 2006, Histochemistry and Cell Biology.

[4]  Arya M. Sharma,et al.  Activation of the peripheral endocannabinoid system in human obesity. , 2005, Diabetes.

[5]  A. Gerber,et al.  Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH) , 2005, International Journal of Obesity.

[6]  K. Mackie,et al.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.

[7]  A. Rissanen,et al.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.

[8]  N. Geary.  Is the control of fat ingestion sexually differentiated? , 2004, Physiology & Behavior.

[9]  C. Flachskamm,et al.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. , 2003, The Journal of clinical investigation.

[10]  N. Saitou,et al.  Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. , 2003, Human molecular genetics.

[11]  P. Arner.  Hunting for human obesity genes? Look in the adipose tissue! , 2000, International Journal of Obesity.

[12]  K. Müller-Vahl,et al.  A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. , 1999, Molecular and cellular probes.

[13]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[14]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[15]  P. Deurenberg,et al.  Changes in fat-free mass during weight loss measured by bioelectrical impedance and by densitometry. , 1989, The American journal of clinical nutrition.